alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 20,376–20,400 of 27,146 studies marked Peer-reviewed (page 816 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Falls in people with Alzheimer’s disease: Exploring the role of inhibitory control

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neuroscience & Biobehavioral Reviews 2025-05-22

On average, people with dementia fall more often than their age-matched peers, with serious consequences, yet the underlying reasons remain poorly understood. 1 key finding →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Understanding rehabilitation and support needs after an episode of delirium: a qualitative thematic analysis of interviews with older people with delirium, family carers and healthcare professionals

✓ Peer-reviewed alzhub usefulness score 40 out of 100. BMC Geriatrics 2025-07-26

Several interconnected themes were identified as potential resources that enable recovery from delirium: (a) social contact and recovery of social lives; (b) the need for information, support, and education; (c) personalisation and personhood; (d) relationship continuity with professional carers; (e) the experience and involvement of carers; and (f) treating the cause and healthy lifestyle. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Bridging Gaps in Sundown Syndrome Research: a Scoping Review and Roadmap for Future Multimodal Approaches

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Archives of Clinical Neuropsychology 2025-06-10

We identified key limitations in traditional assessment methods and classified SS symptoms into five domains: psychomotor symptoms, cognitive and perceptual disturbances, mood and affective symptoms, psychosis, and disruptions in activities of daily living and instrumental activities of daily living. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Delirium: an urgent health priority in Australian hospitals

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Public Health Research & Practice 2026-05-26

Delirium is a common health problem with serious and long-lasting health consequences that disproportionately affects vulnerable population groups (especially older people with dementia or frailty). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Risk Factors for Oropharyngeal Dysphagia in Older Adults - Evidence from Consorci Sanitari Del Maresme and Mataró University Hospital, Catalonia, Spain

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Aging and Disease 2025-01-01

Oropharyngeal dysphagia (OD) is a highly prevalent geriatric syndrome that remains underdiagnosed and undertreated, often resulting in severe nutritional and respiratory complications with poor clinical outcomes. 5 key findings →

Design: narrative review Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Guiding the Ethics of Locator Devices in Dementia Care: Tutorial on Developing a Question-Based Ethical Framework

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Medical Internet Research 2026-07-07

The resulting framework is organized around 3 themes-vision, process, and impact-each containing guiding questions that encourage dialogical reflection and decision-making. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Engaging in the Life-planning in Early Alzheimer’s and other Dementias advance care planning intervention is associated with perceived advance care planning concordance and interpersonal connectedness

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Gerontologist 2025-08-05

N = 48 community-based dyads completed the LEAD intervention, with N = 43 answering open-ended questions. 5 key findings →

Participants: 48 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

End-of Life Care Disparities Experienced by American Indian and Alaska Natives Peoples: An Analysis of Data from the 2019 Medicare Master Beneficiary Summary File

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Palliative Medicine 2025-05-27

AI/AN patients at the end-of-life were more likely to be hospitalized and less likely to use hospice compared with their NHW counterparts. 4 key findings →

Participants: 6,975 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The End of Life With Dementia in Asian Countries: Barriers, Facilitators and a Research Agenda for Advancing a Palliative Approach

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of the American Geriatrics Society 2026-01-13

Broad barriers identified in the outer setting of the implementation framework include sociocultural values and a lack of supportive policies, guidelines, and financing. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of regional white matter hyperintensities and β-amyloid on domain-specific cognition and progression to dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Brain and Cognition 2025-06-24

White matter hyperintensities (WMHs) and cerebral β-amyloid (Aβ) have been characterized as clinically significant biomarkers associated with greater cognitive decline and incidence of Alzheimer's Disease (AD) dementia. 3 key findings →

Participants: 523 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The White Matter Hyperintensity Shape and Brain Clearance (WHIMAS) Study for Identification of Novel 7T Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease: Protocol for a Cross-Sectional Study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. JMIR Research Protocols 2025-12-04

Patient inclusion started in January 2023, and study enrollment of patients is expected to finish in the second quarter of 2027, whereas the main results are expected to be published in the first quarter of 2028. 5 key findings →

Design: cross-sectional Participants: 50 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Harmonization Remains Unresolved: The Case of White Matter Hyperintensity Using ComBat And Deming Regression

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

Using a unique dataset of the same participants scanned close in time on different scanner and protocols, we found that (1) MMD measurements were useful to test the need/improvement due to harmonization; (2) ComBat was not substantially better at creating compatible distributions between scanner vendors than Deming regression, and both were sometimes inadequate. 4 key findings →

Participants: 53 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The burden of stroke, ischaemic heart disease, and dementia in Africa, 1990–2021: an ecological analysis of the Global Burden of Disease 2021

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet Global Health 2025-06-25

In Africa in 2021, 17·3 (95% UI 15·5-19·2) million DALYs were lost due to strokes, 17·6 (15·5-19·6) million were lost due to ischaemic heart diseases, and 1·8 (0·8-4·0) million were lost due to dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence That Changes Clinical Neurology Practice: Translating Algorithms Into Actionable Care

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of clinical neurology (Seoul, Korea) 2026-07-09

Artificial intelligence (AI) has stimulated extensive research in clinical neurology, but relatively few AI systems have meaningfully changed bedside decision-making. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet regional health. Europe 2026-02-24

In 2018, France withdrew reimbursement for cholinesterase inhibitors (ChEIs) in Alzheimer's disease, citing modest efficacy, lack of long-term benefit, and safety concerns. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed